๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

261 VASCULAR ENDOTHELIAL GROWTH FACTOR AS A PREDICTOR OF RESPONSE TO THE COMBINED THERAPY WITH SORAFENIB AND TRANSARTERIAL CHEMOEMBOLIZATION IN PATIENTS WITH HEPATOCELLULAR CARCINOMA

โœ Scribed by Lee, D.; Chung, Y.-H.; Kim, J.A.; Lee, J.-H.; Shin, E.-S.; Shim, J.-H.; Lee, H.C.; Yoon, J.H.; Kim, B.I.; Bae, S.H.; Koh, K.C.; Ryu, S.H.; Park, N.-H.

Book ID
122664297
Publisher
Elsevier Science
Year
2013
Tongue
English
Weight
54 KB
Volume
58
Category
Article
ISSN
0168-8278

No coin nor oath required. For personal study only.

๐Ÿ“œ SIMILAR VOLUMES

Vascular endothelial growth factor is as
Vascular endothelial growth factor is associated with the efficacy of endocrine therapy in patients with advanced breast carcinoma
โœ Peggy Manders; Louk V. A. M. Beex; Vivianne C. G. Tjan-Heijnen; Paul N. Span; C. ๐Ÿ“‚ Article ๐Ÿ“… 2003 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 93 KB ๐Ÿ‘ 2 views

## Abstract ## BACKGROUND Vascular endothelial growth factor (VEGF) is a mediator of angiogenesis and is associated with a poor prognosis in patients with primary breast carcinoma. In the current study, the authors investigated whether there was an association between VEGF levels in tumor tissues